ASCO 2020 Report — Lung Cancer

At this year's meeting of the American Society of Clinical Oncology (ASCO 2020), held virtually May 29–31, investigators discussed the latest findings in cancer research. Associate Editor Anne S. Tsao, MD, reviewed the key presentations on new lung cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.

Adjuvant Osimertinib for EGFR-Mutated Non–Small Cell Lung Cancer

Among patients with early-stage, resectable, non–small cell lung cancer (NSCLC), those with actionable oncogenic driver mutations have not been treated differently in the adjuvant setting than patients with wild-type disease. Herbst and colleagues presented results of an industry-funded, international, double-blind, randomized, controlled, phase III tri…